Exagen Inc. (NASDAQ: XGN) Stock Competitors & Peer Comparison
See XGN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for XGN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XGN | $8.41 | -3.61% | 204.9M | -10.47 | -$0.81 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.63% |
| TMO | $675.25 | +0.04% | 250.9B | 29.30 | $23.16 | +0.27% |
| DHR | $224.87 | +0.17% | 159.9B | 28.50 | $7.98 | +0.63% |
| NTRA | $410.26 | -0.56% | 59B | -311.95 | -$1.32 | N/A |
| A | $175.22 | +1.41% | 49.5B | 30.15 | $5.81 | +0.58% |
| IQV | $269.05 | -0.49% | 44.6B | 22.32 | $12.13 | N/A |
| WAT | $441.09 | +1.74% | 43.5B | 32.38 | $13.68 | N/A |
| IDXX | $534.26 | +2.89% | 41.7B | 37.21 | $14.22 | N/A |
| ILMN | $270.03 | +0.01% | 41.1B | 54.06 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
XGN vs DHR-PB Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, XGN's ROE is -1.22%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, XGN is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for XGN.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
XGN vs TMO Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, TMO has a market cap of 250.9B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while TMO trades at $675.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas TMO's P/E ratio is 29.30. In terms of profitability, XGN's ROE is -1.22%, compared to TMO's ROE of +0.13%. Regarding short-term risk, XGN is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for XGN.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
XGN vs DHR Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, DHR has a market cap of 159.9B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while DHR trades at $224.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas DHR's P/E ratio is 28.50. In terms of profitability, XGN's ROE is -1.22%, compared to DHR's ROE of +0.08%. Regarding short-term risk, XGN is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for XGN.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
XGN vs NTRA Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, NTRA has a market cap of 59B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while NTRA trades at $410.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas NTRA's P/E ratio is -311.95. In terms of profitability, XGN's ROE is -1.22%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, XGN is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for XGN.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
XGN vs A Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, A has a market cap of 49.5B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while A trades at $175.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas A's P/E ratio is 30.15. In terms of profitability, XGN's ROE is -1.22%, compared to A's ROE of +0.20%. Regarding short-term risk, XGN is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for XGN.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
XGN vs IQV Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, IQV has a market cap of 44.6B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while IQV trades at $269.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas IQV's P/E ratio is 22.32. In terms of profitability, XGN's ROE is -1.22%, compared to IQV's ROE of +0.22%. Regarding short-term risk, XGN is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for XGN.Check IQV's competition here
Waters Corporation (NYSE: WAT)
XGN vs WAT Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, WAT has a market cap of 43.5B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while WAT trades at $441.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas WAT's P/E ratio is 32.38. In terms of profitability, XGN's ROE is -1.22%, compared to WAT's ROE of +0.02%. Regarding short-term risk, XGN is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for XGN.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
XGN vs IDXX Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, IDXX has a market cap of 41.7B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while IDXX trades at $534.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas IDXX's P/E ratio is 37.21. In terms of profitability, XGN's ROE is -1.22%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, XGN is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for XGN.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
XGN vs ILMN Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, ILMN has a market cap of 41.1B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while ILMN trades at $270.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas ILMN's P/E ratio is 54.06. In terms of profitability, XGN's ROE is -1.22%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, XGN is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for XGN.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
XGN vs MTD Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, MTD has a market cap of 31.2B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while MTD trades at $1,530.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas MTD's P/E ratio is 35.50. In terms of profitability, XGN's ROE is -1.22%, compared to MTD's ROE of -12.00%. Regarding short-term risk, XGN is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for XGN.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
XGN vs DGX Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, DGX has a market cap of 26.2B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while DGX trades at $233.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas DGX's P/E ratio is 23.44. In terms of profitability, XGN's ROE is -1.22%, compared to DGX's ROE of +0.14%. Regarding short-term risk, XGN is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for XGN.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
XGN vs LH Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while LH trades at $307.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas LH's P/E ratio is 18.37. In terms of profitability, XGN's ROE is -1.22%, compared to LH's ROE of +0.12%. Regarding short-term risk, XGN is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for XGN.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
XGN vs GH Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, GH has a market cap of 23.8B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while GH trades at $176.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas GH's P/E ratio is -50.81. In terms of profitability, XGN's ROE is -1.22%, compared to GH's ROE of +2.11%. Regarding short-term risk, XGN is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for XGN.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
XGN vs EXAS Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas EXAS's P/E ratio is -95.37. In terms of profitability, XGN's ROE is -1.22%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, XGN is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for XGN.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
XGN vs MEDP Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, MEDP has a market cap of 17.2B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while MEDP trades at $618.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas MEDP's P/E ratio is 36.10. In terms of profitability, XGN's ROE is -1.22%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, XGN is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for XGN.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
XGN vs ILMNV Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas ILMNV's P/E ratio is N/A. In terms of profitability, XGN's ROE is -1.22%, compared to ILMNV's ROE of N/A. Regarding short-term risk, XGN is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for XGN.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
XGN vs RVTY Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, RVTY has a market cap of 16.8B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while RVTY trades at $151.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas RVTY's P/E ratio is 28.22. In terms of profitability, XGN's ROE is -1.22%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, XGN is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for XGN.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
XGN vs PKI Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas PKI's P/E ratio is 41.45. In terms of profitability, XGN's ROE is -1.22%, compared to PKI's ROE of +0.03%. Regarding short-term risk, XGN is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for XGN.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
XGN vs CRL Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, CRL has a market cap of 14.2B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while CRL trades at $292.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas CRL's P/E ratio is 29.77. In terms of profitability, XGN's ROE is -1.22%, compared to CRL's ROE of -0.08%. Regarding short-term risk, XGN is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for XGN.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
XGN vs ICLR Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, ICLR has a market cap of 13.4B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while ICLR trades at $171.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas ICLR's P/E ratio is 14.32. In terms of profitability, XGN's ROE is -1.22%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, XGN is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for XGN.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
XGN vs QGEN Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, QGEN has a market cap of 9.3B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while QGEN trades at $44.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas QGEN's P/E ratio is 18.60. In terms of profitability, XGN's ROE is -1.22%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, XGN is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for XGN.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
XGN vs GRAL Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, GRAL has a market cap of 5.7B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while GRAL trades at $135.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas GRAL's P/E ratio is -13.60. In terms of profitability, XGN's ROE is -1.22%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, XGN is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for XGN.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
XGN vs RDNT Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while RDNT trades at $70.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas RDNT's P/E ratio is 156.11. In terms of profitability, XGN's ROE is -1.22%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, XGN is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for XGN.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
XGN vs BLLN Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, BLLN has a market cap of 5.6B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while BLLN trades at $121.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas BLLN's P/E ratio is 173.89. In terms of profitability, XGN's ROE is -1.22%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, XGN is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for XGN.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
XGN vs SHC Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while SHC trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas SHC's P/E ratio is 19.22. In terms of profitability, XGN's ROE is -1.22%, compared to SHC's ROE of +0.27%. Regarding short-term risk, XGN is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for XGN.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
XGN vs SYNH Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas SYNH's P/E ratio is 61.40. In terms of profitability, XGN's ROE is -1.22%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, XGN is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for XGN.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
XGN vs VCYT Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while VCYT trades at $46.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas VCYT's P/E ratio is 22.62. In terms of profitability, XGN's ROE is -1.22%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, XGN is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for XGN.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
XGN vs CDNA Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while CDNA trades at $63.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas CDNA's P/E ratio is 76.90. In terms of profitability, XGN's ROE is -1.22%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, XGN is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for XGN.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
XGN vs OLK Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas OLK's P/E ratio is -96.59. In terms of profitability, XGN's ROE is -1.22%, compared to OLK's ROE of -0.07%. Regarding short-term risk, XGN is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for XGN.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
XGN vs WGS Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while WGS trades at $75.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas WGS's P/E ratio is 238.69. In terms of profitability, XGN's ROE is -1.22%, compared to WGS's ROE of -0.39%. Regarding short-term risk, XGN is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for XGN.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
XGN vs PSNL Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while PSNL trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas PSNL's P/E ratio is -14.97. In terms of profitability, XGN's ROE is -1.22%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, XGN is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for XGN.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
XGN vs OPK Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while OPK trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas OPK's P/E ratio is -6.04. In terms of profitability, XGN's ROE is -1.22%, compared to OPK's ROE of -0.06%. Regarding short-term risk, XGN is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for XGN.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
XGN vs CSTL Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while CSTL trades at $34.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas CSTL's P/E ratio is -54.44. In terms of profitability, XGN's ROE is -1.22%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, XGN is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for XGN.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
XGN vs FLGT Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, FLGT has a market cap of 635M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while FLGT trades at $22.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas FLGT's P/E ratio is 2236.00. In terms of profitability, XGN's ROE is -1.22%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, XGN is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for XGN.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
XGN vs GRALV Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas GRALV's P/E ratio is N/A. In terms of profitability, XGN's ROE is -1.22%, compared to GRALV's ROE of N/A. Regarding short-term risk, XGN is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for XGN.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
XGN vs NEO Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, NEO has a market cap of 495.7M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while NEO trades at $18.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas NEO's P/E ratio is 148.38. In terms of profitability, XGN's ROE is -1.22%, compared to NEO's ROE of -0.06%. Regarding short-term risk, XGN is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for XGN.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
XGN vs MYGN Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, MYGN has a market cap of 400.5M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while MYGN trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas MYGN's P/E ratio is -32.62. In terms of profitability, XGN's ROE is -1.22%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, XGN is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for XGN.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
XGN vs CO Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas CO's P/E ratio is 5.06. In terms of profitability, XGN's ROE is -1.22%, compared to CO's ROE of +0.11%. Regarding short-term risk, XGN is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for XGN.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
XGN vs FLDM Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas FLDM's P/E ratio is -4.74. In terms of profitability, XGN's ROE is -1.22%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, XGN is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for XGN.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
XGN vs BDSX Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, BDSX has a market cap of 247.6M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while BDSX trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas BDSX's P/E ratio is -9.60. In terms of profitability, XGN's ROE is -1.22%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, XGN is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for XGN.Check BDSX's competition here
Freenome, Inc. (NASDAQ: FRNM)
XGN vs FRNM Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, FRNM has a market cap of 132.1M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while FRNM trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas FRNM's P/E ratio is N/A. In terms of profitability, XGN's ROE is -1.22%, compared to FRNM's ROE of N/A. Regarding short-term risk, XGN is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for XGN.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
XGN vs GTH Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas GTH's P/E ratio is -1.11. In terms of profitability, XGN's ROE is -1.22%, compared to GTH's ROE of -1.01%. Regarding short-term risk, XGN is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for XGN.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
XGN vs GENE Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas GENE's P/E ratio is -38.25. In terms of profitability, XGN's ROE is -1.22%, compared to GENE's ROE of -1.85%. Regarding short-term risk, XGN is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for XGN.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
XGN vs IMDX Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, IMDX has a market cap of 102.7M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while IMDX trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas IMDX's P/E ratio is -2.13. In terms of profitability, XGN's ROE is -1.22%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, XGN is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for XGN.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
XGN vs SERA Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, SERA has a market cap of 77.1M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while SERA trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas SERA's P/E ratio is -3.11. In terms of profitability, XGN's ROE is -1.22%, compared to SERA's ROE of -0.47%. Regarding short-term risk, XGN is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for XGN.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
XGN vs PRPO Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, PRPO has a market cap of 43M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while PRPO trades at $23.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas PRPO's P/E ratio is -37.09. In terms of profitability, XGN's ROE is -1.22%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, XGN is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for XGN.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
XGN vs QUCY Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, QUCY has a market cap of 31.2M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while QUCY trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas QUCY's P/E ratio is -0.06. In terms of profitability, XGN's ROE is -1.22%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, XGN is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for XGN.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
XGN vs MDXH Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, MDXH has a market cap of 28.1M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while MDXH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas MDXH's P/E ratio is -0.75. In terms of profitability, XGN's ROE is -1.22%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, XGN is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for XGN.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
XGN vs AKU Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas AKU's P/E ratio is -0.13. In terms of profitability, XGN's ROE is -1.22%, compared to AKU's ROE of -5.32%. Regarding short-term risk, XGN is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for XGN.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
XGN vs BNR Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, BNR has a market cap of 18.6M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while BNR trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas BNR's P/E ratio is -20.26. In terms of profitability, XGN's ROE is -1.22%, compared to BNR's ROE of -0.13%. Regarding short-term risk, XGN is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for XGN.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
XGN vs CEMI Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas CEMI's P/E ratio is -0.63. In terms of profitability, XGN's ROE is -1.22%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, XGN is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for XGN.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
XGN vs ENZ Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas ENZ's P/E ratio is -2.24. In terms of profitability, XGN's ROE is -1.22%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, XGN is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for XGN.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
XGN vs PMD Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas PMD's P/E ratio is -5.24. In terms of profitability, XGN's ROE is -1.22%, compared to PMD's ROE of -0.32%. Regarding short-term risk, XGN is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for XGN.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
XGN vs ME Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas ME's P/E ratio is -0.03. In terms of profitability, XGN's ROE is -1.22%, compared to ME's ROE of -42.03%. Regarding short-term risk, XGN is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for XGN.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
XGN vs MYNZ Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, XGN's ROE is -1.22%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, XGN is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for XGN.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
XGN vs CHEK Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas CHEK's P/E ratio is -0.43. In terms of profitability, XGN's ROE is -1.22%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, XGN is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for XGN.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
XGN vs BIAFW Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, BIAFW has a market cap of 9.8M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while BIAFW trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas BIAFW's P/E ratio is 1.04. In terms of profitability, XGN's ROE is -1.22%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, XGN is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for XGN.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
XGN vs CNTG Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas CNTG's P/E ratio is -0.23. In terms of profitability, XGN's ROE is -1.22%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, XGN is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for XGN.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
XGN vs ADVB Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, ADVB has a market cap of 9.3M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while ADVB trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas ADVB's P/E ratio is -61.18. In terms of profitability, XGN's ROE is -1.22%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, XGN is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for XGN.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
XGN vs NDRA Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while NDRA trades at $5.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas NDRA's P/E ratio is -0.88. In terms of profitability, XGN's ROE is -1.22%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, XGN is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for XGN.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
XGN vs APDN Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas APDN's P/E ratio is -0.10. In terms of profitability, XGN's ROE is -1.22%, compared to APDN's ROE of -7.23%. Regarding short-term risk, XGN is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for XGN.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
XGN vs NVTA Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas NVTA's P/E ratio is -0.00. In terms of profitability, XGN's ROE is -1.22%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, XGN is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for XGN.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
XGN vs LMDX Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas LMDX's P/E ratio is -0.01. In terms of profitability, XGN's ROE is -1.22%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, XGN is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for XGN.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
XGN vs LMDXW Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, XGN's ROE is -1.22%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, XGN is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for XGN.Check LMDXW's competition here
DermTech, Inc. (NASDAQ: DMTK)
XGN vs DMTK Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas DMTK's P/E ratio is -0.04. In terms of profitability, XGN's ROE is -1.22%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, XGN is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for XGN.Check DMTK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
XGN vs BIAF Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, BIAF has a market cap of 3.1M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while BIAF trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas BIAF's P/E ratio is -0.87. In terms of profitability, XGN's ROE is -1.22%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, XGN is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for XGN.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
XGN vs NOTV Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas NOTV's P/E ratio is -0.03. In terms of profitability, XGN's ROE is -1.22%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, XGN is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for XGN.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
XGN vs SQL Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas SQL's P/E ratio is -0.40. In terms of profitability, XGN's ROE is -1.22%, compared to SQL's ROE of -30.46%. Regarding short-term risk, XGN is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for XGN.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
XGN vs AWH Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas AWH's P/E ratio is -0.09. In terms of profitability, XGN's ROE is -1.22%, compared to AWH's ROE of +1.62%. Regarding short-term risk, XGN is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for XGN.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
XGN vs HTGM Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas HTGM's P/E ratio is -0.03. In terms of profitability, XGN's ROE is -1.22%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, XGN is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for XGN.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
XGN vs BIOC Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas BIOC's P/E ratio is -0.01. In terms of profitability, XGN's ROE is -1.22%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, XGN is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for XGN.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
XGN vs SQLLW Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, XGN's ROE is -1.22%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, XGN is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for XGN.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
XGN vs ISPC Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, ISPC has a market cap of 165.2K. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while ISPC trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas ISPC's P/E ratio is -0.04. In terms of profitability, XGN's ROE is -1.22%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, XGN is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for XGN.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
XGN vs WGSWW Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, XGN's ROE is -1.22%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, XGN is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for XGN.Check WGSWW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
XGN vs NDRAW Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas NDRAW's P/E ratio is N/A. In terms of profitability, XGN's ROE is -1.22%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, XGN is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for XGN.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
XGN vs PRXL Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas PRXL's P/E ratio is 42.97. In terms of profitability, XGN's ROE is -1.22%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, XGN is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for XGN.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
XGN vs MEUSW Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas MEUSW's P/E ratio is N/A. In terms of profitability, XGN's ROE is -1.22%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, XGN is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for XGN.Check MEUSW's competition here
Danaher Corporation (NYSE: DHR-PA)
XGN vs DHR-PA Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, XGN's ROE is -1.22%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, XGN is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for XGN.Check DHR-PA's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
XGN vs BNGOW Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas BNGOW's P/E ratio is N/A. In terms of profitability, XGN's ROE is -1.22%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, XGN is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for XGN.Check BNGOW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
XGN vs OCDX Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas OCDX's P/E ratio is -42.28. In terms of profitability, XGN's ROE is -1.22%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, XGN is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for XGN.Check OCDX's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
XGN vs CHEKZ Comparison September 2026
Exagen Inc. (NASDAQ: XGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XGN stands at 204.9M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, XGN is priced at $8.41 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XGN currently has a P/E ratio of -10.47, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, XGN's ROE is -1.22%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, XGN is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for XGN.Check CHEKZ's competition here